Status:
COMPLETED
Brain Stimulation For Cancer Smokers
Lead Sponsor:
Medical University of South Carolina
Conditions:
Cancer of Head and Neck
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Smoking cessation and relapse prevention represent and important opportunity to improve cancer survival rates, reduce the risk of cancer treatment complication, and improve the quality of life of pati...
Detailed Description
Specific aims: Smoking cessation and relapse prevention represent and important opportunity to improve cancer survival rates , reduce the risk of cancer treatment complication, and improve the quality...
Eligibility Criteria
Inclusion
- 1\. Completed cancer treatment (e.g. surgery, chemotherapy and radiation) \> 6 months Patients with current endocrine therapy will be included for the study.
- 2\. Have been diagnosed with noninvasive or invasive (Stage 1, 2, or 3A) breast cancer or prostate cancer.
- 3\. Smoke 5 or more cigarettes per day and have a carbon monoxide (CO) level \> 5 ppm indicative of recent smoking.
- 4\. Not have received substance abuse treatment within the previous 30 days. 5. Meet criteria for low to moderate nicotine dependence as determined by FTND ≥1.
- 6\. Be willing to provide informed consent. 7. Be able to comply with protocol requirements and likely to complete all study procedures.
- 8\. Is willing to consider trying to quit smoking. 9. Have no active cardiac, neurologic, or psychiatric illness. 10. 0.5-10 years post diagnosis of cancer at the time enrollment.
Exclusion
- Current dependence, defined by Diagnostic and Statistical manual of Mental Disorders (DSM)-V criteria, on any psychoactive substances other than nicotine or caffeine.
- Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \> 15 minutes, implanted electronic device, metal in the head, or pregnancy).
- History of autoimmune, endocrine, viral, or vascular disorder affecting the brain.
- History of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.
Key Trial Info
Start Date :
October 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 20 2020
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03419741
Start Date
October 21 2017
End Date
October 20 2020
Last Update
May 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425